The results showed that this formulation successfully improved the pharmacodynamics and pharmacokinetics of osthole, reducing amyloid beta in APP/PS1 mice and therefore indicating that it could be a potential strategy for addressing AD [42]. The gene discussed is APP; the disease is Alzheimer disease.